Acumen Research and Consulting Genetic Testing Market is Anticipated to Surpass U | Page 3

because people are increasingly aware of health and the incidence of mortality due to genetic diseases worldwide. On the other hand, during the forecast period the pharmacogenomic test segment is expected to be the highest CAGR. This is largely because pharmaceutical companies are increasingly applying drugs and developing them. Regional Stance The markets in North America, Europe, Asia-Pacific and LAMEA are assessed on the grounds of geography. North America was the global leader in the genetic testing market in 2018 and will dominate the forecasting period. The majority of key players in this region are attributed to this. However, as a result of the increase of accessibility, increased health expenditure and increased attention to early screening of genetic disorders, Asia-Pacific is expected to grow in the highest CAGR over the projected timeframe. In addition, the number of visitors to the cholera-affected countries is rising and the need for immunization is increasing in turn. Browse All official Market Research Reports Press Releases@ https://www.acumenresearchandconsulting.com/press-releases Key Players & Strategies 23andMe, Abbott Molecular, Biocartis, BioHelix, Bayer Diagnostics, BioMerieux, BGI, Celera Genomics, Cepheid, Counsyl, deCODEme, Genentech, Genomictree, HTG Molecular Diagnostics, Luminex, MolecularTM, IntegraGen, LabCorp diagnostics, Myriad, Natera, PacBio, Pathway Geneomaics, Qiagen, Roche Diagnostic is among the most eminent players in the global genetic testing market. Industry players focus on the strategic expansion of their product portfolio through acquisitions, fusions and collaborations. Roche, for example, in December 2018, acquired the Non-invasive Prenatal (NIPT) and cell-free DNA testing services market Ariosa Diagnostics, a provider of molecular diagnostic testing services. Would like to place an order or any question, please feel free to contact at [email protected] | [phone]